Literature DB >> 15699426

Evaluation of western blot CagA seropositivity in Helicobacter pylori-seropositive and -seronegative subjects.

J Henrik Simán1, Lars Engstrand, Göran Berglund, Claes-Henrik Florén, Arne Forsgren.   

Abstract

CagA seropositivity is an important risk factor for gastric adenocarcinoma and duodenal ulcer. However, CagA seropositivity is also found in Helicobacter pylori-seronegative subjects. Is CagA seropositivity in these subjects a sign of a past H. pylori infection, or does it represent a false-positive reaction? This study investigates the intensity of the CagA immune reaction and the variation in CagA seroprevalence with year of birth for 650 subjects belonging to the Malmo Preventive Medicine cohort. CagA and H. pylori seroprevalences were determined by Western blot analysis (Helicoblot 2.1) and enzyme-linked immunosorbent assay. The peak intensity of the CagA band was significantly lower in H. pylori-seronegative subjects than in those with concomitant H. pylori seropositivity. In H. pylori-seropositive subjects, peak CagA intensity had a bimodal distribution. The prevalence of CagA-seropositive but H. pylori-seronegative subjects increased successively and significantly with year of birth, in contrast to the prevalence of CagA-seropositive and H. pylori-seropositive subjects, which decreased significantly. However, within H. pylori-seropositive and -seronegative subgroups, CagA seroprevalences were constant for different birth cohorts. If CagA seropositivity in H. pylori-seronegative subjects represents a past H. pylori infection, there must have been some mechanisms of eradication that were more common in younger subjects and that were of more importance than the presence of gastric atrophy and the longer duration and higher prevalence of H. pylori infection found in older subjects. Antibiotic treatment of H. pylori was not common practice at the time of enrollment. On the other hand, a false-positive reaction would be constant and independent of birth cohorts, as with the H. pylori-seronegative subgroup of our study. Peak CagA intensity in H. pylori-seronegative subjects corresponded to the lower part of the bimodal distribution of peak CagA intensity in H. pylori-seropositive subjects. We conclude that a major proportion of CagA seropositivity in H. pylori-seronegative subjects represents a false-positive reaction. Peak CagA intensity has a bimodal distribution in H. pylori-seropositive subjects. Low-intensity CagA seropositivity in H. pylori-seropositive subjects is indeterminate, representing both false-positive and true-positive reactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699426      PMCID: PMC549300          DOI: 10.1128/CDLI.12.2.304-309.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  13 in total

1.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.

Authors:  J Parsonnet; G D Friedman; N Orentreich; H Vogelman
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Campylobacter pylori in Swedish patients referred for gastroscopy.

Authors:  H Gnarpe; P Unge; C Blomqvist; S Mäkitalo
Journal:  APMIS       Date:  1988-02       Impact factor: 3.205

3.  The diagnostic value of enzyme immunoassay and immunoblot in monitoring eradication of Helicobacter pylori.

Authors:  M Sörberg; L Engstrand; M Ström; K A Jönsson; H Jörbeck; M Granström
Journal:  Scand J Infect Dis       Date:  1997

4.  Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease.

Authors:  Abraham M Y Nomura; Guillermo I Pérez-Pérez; James Lee; Grant Stemmermann; Martin J Blaser
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

Review 5.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.

Authors: 
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

6.  Association between Helicobacter pylori and gastric carcinoma in the city of Malmö, Sweden. A prospective study.

Authors:  J H Simán; A Forsgren; G Berglund; C H Florén
Journal:  Scand J Gastroenterol       Date:  1997-12       Impact factor: 2.423

7.  Risk of gastric cancer among smokers infected with Helicobacter pylori.

Authors:  Hermann Brenner; Voler Arndt; Günter Bode; Christa Stegmaier; Hartwig Ziegler; Til Stümer
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

8.  Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.

Authors:  W A Stack; J C Atherton; G M Hawkey; R F A Logan; C J Hawkey
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

9.  Assessment of Helicobacter pylori vacA and cagA genotypes and host serological response.

Authors:  C Figueiredo; W Quint; N Nouhan; H van den Munckhof; P Herbrink; J Scherpenisse; W de Boer; P Schneeberger; G Perez-Perez; M J Blaser; L J van Doorn
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection.

Authors:  A M Ekström; M Held; L E Hansson; L Engstrand; O Nyrén
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

View more
  4 in total

1.  Evaluation of the Aspergillus Western blot IgG kit for diagnosis of chronic aspergillosis.

Authors:  A Oliva; P Flori; C Hennequin; J-C Dubus; M Reynaud-Gaubert; D Charpin; J M Vergnon; P Gay; A Colly; R Piarroux; H Pelloux; S Ranque
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Role of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in Mexican patients.

Authors:  Roberto Herrera-Goepfert; Jesus-K Yamamoto-Furusho; Luis-F Onate-Ocana; Margarita Camorlinga-Ponce; Leopoldo Munoz; Jorge-A Ruiz-Morales; Gilberto Vargas-Alarcon; Julio Granados
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection.

Authors:  Lea Veijola; Aino Oksanen; Pentti Sipponen; Hilpi Rautelin
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

4.  Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection.

Authors:  Lea Irene Veijola; Aino Mirjam Oksanen; Pentti Ilmari Sipponen; Hilpi Iris Kaarina Rautelin
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.